A DUE

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Contact phone
Sparrow Clinical Research Institute 517-364-5760
Principal investigator
Dr. Chad Link, DO, FACC
Trial Category
Heart & Vascular
Trial SubCategory
Pulmonary Hypertension